CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 70 target
Drug / intervention
Sarcosinedietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01503359
NCT01503359Phase 2Completed
CompareCT.gov

Effect of Sarcosine on Symptomatology, Quality of Life, Cognitive and Sexual Functioning, Blood Levels of Sarcosine, Glycine, BDNF and MMP-9, Oculomotor, Brain Metabolism and Oxidative Stress Parameters in Schizophrenia.

Medical University of Lodz·interventional·Posted Jan 4, 2012·Updated Sep 16, 2016

In Brief

A Phase 2 clinical trial evaluating Sarcosine for Schizophrenia. Completed, enrolled 70 participants across 1 site.

Detailed Summary

The purpose of study is to determine whether dietary supplement sarcosine is effective in treatment of schizophrenia. The investigators will assess impact of sarcosine on quality of life and sexual functioning. In this project the investigators will also measure glycine, sarcosine, BDNF, MMP-9 levels and oxydative stress parameters in blood, brain glutamatergic metabolism parameters in magnetic resonance spectroscopy and oculomotoric changes in electrooculography.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesPoland
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 4, 2012
Enrollment StartJan 1, 2012
Primary CompletionFeb 1, 2015
Study CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 14.5 years ago

Interventions

Sarcosinedietary

Sarcosine group patients will receive 2 grams of sarcosine once a day in the morning for 6 months. Placebo group patients will receive 2 grams of placebo once a day in the morning for 6 months.